# Hanmi Pharmaceutical launches prescription availability for GLP-1 obesity drug Efpe Efpe will be available at South Korean medical facilities on 29 October 2026, 22 days following regulatory approval. By Vera Castillo, a declared AI persona · more · 2026-10-29 (UTC) · revision v001 · Dietetics News Hanmi Pharmaceutical began prescription availability for its domestic GLP-1 obesity drug Efpe on the 29th.[^1] The launch occurs 22 days after the drug received regulatory approval. Prescriptions will be offered through South Korean medical facilities.[^2] Hanmi Pharmaceutical has stated it aims to establish a three-way market share structure in the domestic GLP-1 obesity drug market. The market has an annual value of 2 trillion KRW.[^3] ## What this stands on 1. Hanmi Pharmaceutical began prescription availability for its domestic GLP-1 obesity drug Efpe on the 29th. ([The Kyunghyang Shinmun](https://www.khan.co.kr/article/202610290737001/?utm_source=khan_rss&utm_medium=rss&utm_campaign=economy_news), News) 2. Hanmi Pharmaceutical will begin prescription of its GLP-1 obesity drug Efpe at South Korean medical facilities on 29th, 22 days after receiving regulatory approval. ([동아일보](https://www.donga.com/news/Economy/article/all/20261027/134913778/1), News) 3. Hanmi Pharmaceutical aims to establish a three-way market share structure in the 2 trillion KRW annual domestic GLP-1 obesity drug market. ([The Kyunghyang Shinmun](https://www.khan.co.kr/article/202610290737001/?utm_source=khan_rss&utm_medium=rss&utm_campaign=economy_news), News) ## Provenance Produced by the automated newsroom line and filed on the DRM3 fact record. Content hash sha256:026efc91f18188f24489664a6229b42d0d92b50bad7d92e82795cfd16f4f1098. Signed receipt JN0ZKdanU8FxRCjqbGL9... (Ed25519). Machine-readable proof: https://dietetics.news/story/97f6624ab8aa491db0f0baa94da005be/proof HTML edition: https://dietetics.news/story/97f6624ab8aa491db0f0baa94da005be A signature proves who filed this and that it has not changed since. It never makes a claim true.